Cue Biopharma, Inc. — Q1 2019 Form 10-Q
Reporting period: Three months ended March 31, 2019. Cue is a development-stage biopharmaceutical company developing its Immuno-STAT platform and had no commercial product sales. Its candidates were described as preclinical; management planned to file an IND for CUE-101 and begin clinical trials in the first half of 2019.
Financial performance and liquidity
| Metric | Q1 2019 | Q1 2018 or comparison |
|---|---|---|
| Collaboration revenue | $0.370 million | $0; Q1 2019 revenue was from Merck services |
| Operating expenses | $11.797 million | $7.522 million |
| Research and development | $8.353 million | $5.819 million |
| General and administrative | $3.444 million | $1.703 million |
| Net loss | $11.267 million | $7.523 million |
| Loss per share, basic and diluted | $0.54 | $0.37 |
| Cash used in operating activities | $8.475 million | $9.759 million |
At March 31, 2019, cash and cash equivalents were $21.913 million and short-term marketable securities were $8.966 million, totaling approximately $30.879 million. Management said these resources should fund operations for at least 12 months from the financial statements’ issuance. The company reported no debt. Stockholders’ equity was $24.738 million, down from $33.972 million at December 31, 2018; accumulated deficit was $83.068 million.
Operating expenses rose by $4.275 million year over year as the company expanded its activities. R&D increased $2.534 million and G&A increased $1.741 million. The larger net loss reflected this spending increase, partly offset by collaboration revenue and investment income. No meaningful operating margin is presented for this development-stage business.
Material developments and unusual items
- Q1 operating cash use improved by $1.284 million year over year. Investing activities provided $9.481 million, primarily from redemption of $9.500 million in short-term investments; this was a shift between cash and investments, not operating revenue.
- Under the Merck collaboration, Cue recognized $0.370 million of revenue in the quarter. Merck’s original $2.5 million upfront payment remained subject to performance obligations; the company reported additional research and development contract liabilities.
- The LG Chem oncology collaboration generated no Q1 revenue. The agreement includes a $5 million upfront cash payment, a $5 million equity investment, potential milestones of up to $400 million and tiered royalties, subject to the agreement’s terms and successful development.
- Adoption of ASC 842 on January 1, 2019 added a right-of-use asset of approximately $9.692 million and lease liability of approximately $9.347 million at adoption. At March 31, the reported asset was $8.691 million and lease liability was $8.590 million. Future lease payments totaled $9.184 million before discounting.
- Stock-based compensation was $1.768 million in Q1 2019 versus $1.158 million a year earlier. Unrecognized compensation of approximately $16.123 million was expected to be expensed through July 2022.
Outlook, risks and contingencies
Management expected R&D and G&A expenses to increase as development and operations expand. Cue expects to need additional capital until it can generate sustainable revenue and positive operating cash flow; financing may come from equity, debt, collaborations or licensing. The company cautioned that financing may not be available on acceptable terms, and equity financing could dilute existing holders. It also cited clinical, regulatory, safety, development, collaboration and commercialization risks. The filing reported no material change to previously disclosed risk factors, no material legal proceedings and no accrued contingent liabilities. Disclosure controls were assessed as effective as of March 31, 2019.
Key facts for investors to verify
- Whether CUE-101’s planned IND filing and clinical-trial start in the first half of 2019 occurred, and any resulting regulatory or trial updates.
- Subsequent cash use, financing needs and whether the stated 12-month runway remains sufficient.
- Progress and revenue recognition under the Merck and LG Chem agreements, including the status of milestones and performance obligations.
- Whether R&D spending, lease obligations and stock-based compensation develop in line with management’s expectations.